Meniscal repair device and method
Methods and apparatus for treating meniscal tissue damage are disclosed, including a biocompatible meniscal repair device comprising a stent. The tissue repair device is adapted to be placed in contact with a defect in the meniscus and can preferably provide a structure for supporting meniscal tissue and/or encouraging tissue growth through contact with vascularized portions of the meniscus or as a conduit for introduction of exogenous healing therapies.
1 . A biocompatible meniscal repair device, comprising:
a biocompatible tissue repair stent adapted to be placed in contact with a defect in a meniscus and adapted to contact a vascularized portion of the meniscus and communicate biological materials from the vascularized portion of the meniscus to the tissue defect in the meniscus.
2 . The repair device of claim 1 , wherein the stent provides a conduit that enables blood, cells or nutrients to migrate from the vascularized portion of the meniscus to the tissue defect in the meniscus.
3 . The repair device of claim 2 , wherein the stent is adapted to contact the synovium.
4 . The repair device of claim 1 , wherein the tissue repair stent is constructed from a bioabsorbable material.
5 . The repair device of claim 1 , wherein the tissue repair stent is constructed from a non-bioabsorbable material.
6 . The repair device of claim 1 , wherein the tissue repair stent is in-situ expandable.
7 . The repair device of claim 1 , wherein the tissue repair stent is a non-porous tube.
8 . The repair device of claim 1 , wherein the tissue repair stent is a tube with porous walls.
9 . The repair device of claim 1 , wherein the tissue repair stent comprises a mesh.
10 . The repair device of claim 4 wherein the tissue repair stent includes at least one polymer derived from monomers selected from the group consisting of caprolactone, glycolide, lactide, dioxanone and mixtures thereof.
11 . The repair device of claim 1 , wherein the tissue repair stent comprises polydioxanone.
12 . The repair device of claim 1 , wherein the tissue repair stent comprises a copolymer of glycolide and L-lactide.
13 . The repair device of claim 1 , wherein the tissue repair stent is formed from at least one material selected from the group consisting of natural polymers, synthetic polymers, and combinations thereof.
14 . The device of claim 13 wherein the material is SIS.
15 . The repair device of claim 1 , further comprising a viable tissue disposed on or within the tissue repair stent and effective to integrate with native tissue adjacent to the tissue repair stent.
16 . The repair device of claim 1 , further comprising at least one bioactive substance effective to stimulate cell growth.
17 . The repair device of claim 16 , wherein the bioactive substance is selected from the group consisting of bone morphogenic proteins, VEGF, PDGF, TGF-β, platelet rich plasma, cartilage-derived morphogenic proteins, recombinant human growth factors, and combinations thereof.
18 . The repair device of claim 17 , wherein the bioactive substance is selected from the group consisting of rhGDF-5, BMP-2, BMP-7, and CDMP-1.
19 . The repair device of claim 1 , wherein the tissue repair stent is a porous matrix capable encouraging migration of blood, cells, or nutrients from one end of the stent to another end.
20 . The repair device of claim 19 , wherein the matrix comprises a bioactive agent.
21 . The repair device of claim 19 , wherein the stent has a hollow core.
22 . The repair device of claim 1 , wherein the stent has barbs on its outer surface to encourage fixation within the meniscus.
23 . The repair device of claim 1 , wherein the stent is is made of a shape memory material.
24 . The repair device of claim 23 , wherein the shape memory material comprises a metal.
25 . The repair device of claim 24 , wherein the shape memory material is nitinol.
26 . The repair device of claim 23 , wherein the shape memory material comprises a polymer.
27 . A method of surgically repairing meniscal defects, comprising:
providing a tissue repair stent;
positioning a first end of the tissue repair stent in contact with the defect in the meniscus while positioning a second end of the stent in contact with a vascularized portion of the meniscus, wherein the stent allows blood, cells or nutrients to migrate from the vascularized portion of the meniscus to the defect in the meniscus and thereby encourage healing of the meniscus.
28 . The method of claim 27 , further comprising the step of rasping the meniscus before or after positioning the stent.
29 . The method of claim 27 , further comprising placing the second end of the stent in contact with the synovium.
30 . The method of claim 29 , further comprising the step of rasping the synovium before or after positioning the stent.
31 . The method of claim 29 , wherein the stent provides a conduit that enables blood, cells or nutrients to migrate from the synovium to the tissue defect in a meniscus.
32 . The method of claim 27 , wherein the blood, cells, or nutrients are provided from an exogenous source.
33 . A method of surgically repairing meniscal defects, comprising:
creating a channel or slice in the meniscus between the defect in the meniscus and a vascularized portion of the meniscus, and
providing a material in the channel or slice to permit controlled patency of the channel or slice to enhance migration of blood, cells, or nutrients from the vascularized portion of the meniscus to the defect in is the meniscus and thereby encourage healing of the meniscal defect.
34 . The method of claim 33 wherein the material is an anticoagulant, enzyme, or gel.
35 . The method of claim 34 , wherein the material is a gel.
36 . The method of claim 34 , wherein the anticoagulant is selected from the group consisting of acid citrate dextrose (ACD), citrate phosphate dextrose (CPD), citrate, heparin, potassium oxalate, potassium citrate, potassium ethylene diamine tetraacetic acid (EDTA) and combinations thereof.
37 . The method of claim 34 , wherein the enzyme is selected from the group consisting of collagenase, chondroitinase, trypsin, elastase, hyaluronidase, peptidase, thermolysin, matrix metalloproteinase, gelatinase, protease, and combinations thereof.
38 . The method of claim 33 , wherein the material further comprises a bioactive substance selected from the group consisting of bone morphogenic proteins, VEGF, PDGF, TGF-β, platelet rich plasma, cartilage-derived morphogenic proteins, recombinant human growth factors, and combinations thereof.
39 . The method of claim 38 , wherein the bioactive substance is selected from the group consisting of rhGDF-5, BMP-2, BMP-7, and CDMP-1.
40 . The method of claim 38 , wherein the bioactive agent is in a gel carrier.